The expanding role of complement inhibitors in the treatment of IgA nephropathy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41722940.
- Also identified by DOI 10.1016/j.kint.2025.12.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Complement activation has emerged as a key driver of IgA nephropathy, catalyzing the rapid expansion of complement-targeted therapies. Barbour et al. reported promising phase 2 results of sefaxersen, an antisense inhibitor of Factor B, showing reduced proteinuria, improved hematuria, and sustained alternative-pathway inhibition. Nonetheless, as the therapeutic landscape expands, advancing precision medicine in IgA nephropathy will require defining appropriate patient profiles and predictors of therapeutic response to guide individualized treatment.
Medical subject headings
- Glomerulonephritis, IGA
- Complement Inactivating Agents
- Complement Activation
- Complement Factor B
- Oligonucleotides, Antisense